Results 121 to 130 of about 82,474 (317)

Computational Drug Repositioning in Cardiorenal Disease: Opportunities, Challenges, and Approaches

PROTEOMICS, EarlyView.
Paul Perco, Matthias Ley, Kinga Kęska‐Izworska, Dorota Wojenska, Enrico Bono, Samuel M. Walter, Lucas Fillinger, Klaus Kratochwill   +7 more
wiley   +1 more source

Estimating the association and timing of occurrence between obesity and related comorbidity outcomes in a real‐world setting: A cohort study in the United States

Clinical Obesity, EarlyView.
Estimating the Association and Timing of Occurrence between Obesity and Related Comorbidity Outcomes in a Real‐World Setting: A Cohort Study in the United States. An observational, retrospective cohort study of adults with available body mass index (BMI) data during the period 2010–2019 in a large United States claims‐linked electronic health records ...
Firas Dabbous, Jigish Bhavsar, Jayashri Desai, Anthony Fabricatore, Bríain Ó. Hartaigh, Wojciech Michalak, Sariya Udayachalerm, Cynthia Saiontz‐Martinez, Zhenxiang Zhao, Fatima Cody Stanford   +9 more
wiley   +1 more source

Hypernephroma in a Polycystic Kidney: Case Report [PDF]

, 1945
William Baurys
openalex   +1 more source

Lactate and Lactylation in AKI‐to‐CKD: Epigenetic Regulation and Therapeutic Opportunities

Cell Proliferation, EarlyView.
ABSTRACT Lactate is not only a byproduct of glycolysis, but is also considered an energy source, gluconeogenic precursor, signalling molecule and protein modifier during the process of cellular metabolism. The discovery of lactylation reveals the multifaceted functions of lactate in cellular metabolism and opens new avenues for lactate‐related research.
Yi Hou, Dongwei Liu, Zuishuang Guo, Cien Wei, Fengyu Cao, Yue Xu, Qi Feng, Fengxun Liu   +7 more
wiley   +1 more source

Discussion on Polycystic Disease of the Kidneys [PDF]

, 1924
Graham J. Forbes
openalex   +1 more source

Developments in albuminuria testing: A key biomarker for detection, prognosis and surveillance of kidney and cardiovascular disease—A practical update for clinicians

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Albuminuria, the abnormal presence of albumin in urine, is a key marker of kidney damage and a strong predictor of kidney and cardiovascular outcomes. Its clinical significance has evolved from early historical observations to its current role in chronic kidney disease (CKD) detection, risk stratification and treatment monitoring.
Jelle M. Beernink, Dominique van Mil, Gozewijn D. Laverman, Hiddo J. L. Heerspink, Ron T. Gansevoort   +4 more
wiley   +1 more source

Polycystic Disease of the Liver, Pancreas and Kidneys [PDF]

, 1939
Manville W. Norton
openalex   +1 more source

Transitional changes in medication‐initiator cohort profiles in persons with chronic kidney disease and type 2 diabetes—A hospital‐based cohort study in Japan

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims To describe temporal changes in the characteristics of medication‐initiator cohorts in persons with chronic kidney disease (CKD) and type 2 diabetes (T2D). Materials and Methods Adults with CKD and T2D initiating sodium‐glucose cotransporter‐2 inhibitors (SGLT‐2i) or glucagon‐like peptide‐1 receptor agonists (GLP‐1RA) were identified in ...
Yuichiro Yano, Suguru Okami, Hiroshi Kanegae, Nikolaus G. Oberprieler, Catherine Johannes, Satoshi Yamashita, Kanae Yoshikawa‐Ryan, Csaba P. Kovesdy, David Vizcaya, Naoki Kashihara   +9 more
wiley   +1 more source

Familial Visual Defects Associated with Polycystic Kidney and Medullary Sponge Kidney [PDF]

, 1963
K. F. Fairley, P. W. Leighton, Priscilla Kincaid‐Smith   +2 more
openalex   +1 more source

Effects of combined treatment with zibotentan and dapagliflozin compared to dapagliflozin alone in patients with diabetic and non‐diabetic chronic kidney disease

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims To evaluate whether type 2 diabetes status modifies the efficacy and safety of combining zibotentan (zibo), a selective endothelin receptor antagonist, and dapagliflozin (dapa) compared to placebo plus dapagliflozin in individuals with chronic kidney disease (CKD).
Victor Wasehuus, J. David Smeijer, Phil Ambery, Peter J. Greasley, Emma Wijkmark, David C. Wheeler, Peter Rossing, Hiddo J. L. Heerspink   +7 more
wiley   +1 more source